Literature DB >> 19903103

Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses.

Yun Lin1, Humilidad F Gallardo, Geoffrey Y Ku, Hao Li, Gregor Manukian, Teresa S Rasalan, Yinyan Xu, Stephanie L Terzulli, Lloyd J Old, James P Allison, Alan N Houghton, Jedd D Wolchok, Jianda Yuan.   

Abstract

BACKGROUND AIMS: Monitoring cellular immune responses is one prerequisite for the rational development of cancer vaccines.
METHODS: We describe an extensive effort to optimize and validate quantitatively an in vitro T-cell culture method by determining the phenotype and function of both CD4(+) and CD8(+) T cells, including measurement of the phenotype markers CCR7, CD45RA, CD28 and CD27 and the functional markers interferon (IFN)-gamma, interleukin (IL)-2, macrophage inflammatory protein (MIP)-1beta, tumor necrosis factor (TNF)-alpha and CD107a.
RESULTS: Autologous peripheral blood mononuclear cells (PBMC) were potent stimulators that expanded antigen (Ag)-specific CD8(+) T cells during short-term culture with the addition of IL-2 and IL-15 cytokines. Polyfunctional Ag-specific CD4(+) and CD8(+) T cells were detectable using this method.
CONCLUSIONS: Our culture system represents a robust human T-cell culture protocol that permits phenotypic, quantitative and qualitative evaluation of vaccine-induced CD4(+) and CD8(+) T-cell responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903103      PMCID: PMC2932850          DOI: 10.3109/14653240903136987

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  29 in total

Review 1.  The role of chemokine receptors in primary, effector, and memory immune responses.

Authors:  F Sallusto; C R Mackay; A Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

2.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions.

Authors:  F Sallusto; D Lenig; R Förster; M Lipp; A Lanzavecchia
Journal:  Nature       Date:  1999-10-14       Impact factor: 49.962

3.  Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells.

Authors:  Delphine Sauce; Nathalie Rufer; Patricia Mercier; Marie Bodinier; Jean-Paul Rémy-Martin; Anne Duperrier; Christophe Ferrand; Patrick Hervé; Pedro Romero; François Lang; Pierre Tiberghien; Eric Robinet
Journal:  Blood       Date:  2003-05-01       Impact factor: 22.113

4.  Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation.

Authors:  Michael R Betts; Jason M Brenchley; David A Price; Stephen C De Rosa; Daniel C Douek; Mario Roederer; Richard A Koup
Journal:  J Immunol Methods       Date:  2003-10-01       Impact factor: 2.303

5.  Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

Authors:  E Jäger; Y Nagata; S Gnjatic; H Wada; E Stockert; J Karbach; P R Dunbar; S Y Lee; A Jungbluth; D Jäger; M Arand; G Ritter; V Cerundolo; B Dupont; Y T Chen; L J Old; A Knuth
Journal:  Proc Natl Acad Sci U S A       Date:  2000-04-25       Impact factor: 11.205

6.  Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance.

Authors:  Alfred Zippelius; Pascal Batard; Verena Rubio-Godoy; Gilles Bioley; Danielle Liénard; Ferdy Lejeune; Donata Rimoldi; Philippe Guillaume; Norbert Meidenbauer; Andreas Mackensen; Nathalie Rufer; Norbert Lubenow; Daniel Speiser; Jean-Charles Cerottini; Pedro Romero; Mikaël J Pittet
Journal:  Cancer Res       Date:  2004-04-15       Impact factor: 12.701

Review 7.  Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

Authors:  Pedro Romero; Danila Valmori; Mikael J Pittet; Alfred Zippelius; Donata Rimoldi; Frederic Lévy; Valérie Dutoit; Maha Ayyoub; Verena Rubio-Godoy; Olivier Michielin; Philippe Guillaume; Pascal Batard; Immanuel F Luescher; Ferdy Lejeune; Danielle Liénard; Nathalie Rufer; Pierre-Yves Dietrich; Daniel E Speiser; Jean-Charles Cerottini
Journal:  Immunol Rev       Date:  2002-10       Impact factor: 12.988

Review 8.  Tricks with tetramers: how to get the most from multimeric peptide-MHC.

Authors:  Linda Wooldridge; Anna Lissina; David K Cole; Hugo A van den Berg; David A Price; Andrew K Sewell
Journal:  Immunology       Date:  2009-02       Impact factor: 7.397

Review 9.  T-cell responses of vaccinated cancer patients.

Authors:  Pierre G Coulie; Pierre van der Bruggen
Journal:  Curr Opin Immunol       Date:  2003-04       Impact factor: 7.486

Review 10.  Central memory and effector memory T cell subsets: function, generation, and maintenance.

Authors:  Federica Sallusto; Jens Geginat; Antonio Lanzavecchia
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

View more
  21 in total

1.  Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Authors:  Jianda Yuan; Matthew Adamow; Brian A Ginsberg; Teresa S Rasalan; Erika Ritter; Humilidad F Gallardo; Yinyan Xu; Evelina Pogoriler; Stephanie L Terzulli; Deborah Kuk; Katherine S Panageas; Gerd Ritter; Mario Sznol; Ruth Halaban; Achim A Jungbluth; James P Allison; Lloyd J Old; Jedd D Wolchok; Sacha Gnjatic
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-20       Impact factor: 11.205

2.  Primed tumor-reactive multifunctional CD62L+ human CD8+ T cells for immunotherapy.

Authors:  Matthias Wölfl; Katharina Merker; Henner Morbach; Stefaan W Van Gool; Matthias Eyrich; Philip D Greenberg; Paul G Schlegel
Journal:  Cancer Immunol Immunother       Date:  2010-10-24       Impact factor: 6.968

3.  IL-7 signaling imparts polyfunctionality and stemness potential to CD4(+) T cells.

Authors:  Zhi-Chun Ding; Chufeng Liu; Yang Cao; Tsadik Habtetsion; Michal Kuczma; Wenhu Pi; Heng Kong; Ercan Cacan; Susanna F Greer; Yan Cui; Bruce R Blazar; David H Munn; Gang Zhou
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

4.  A phase 1 study of a vaccine targeting preferentially expressed antigen in melanoma and prostate-specific membrane antigen in patients with advanced solid tumors.

Authors:  Jeffrey S Weber; Nicholas J Vogelzang; Marc S Ernstoff; Oscar B Goodman; Lee D Cranmer; John L Marshall; Sabrina Miles; Dar Rosario; David C Diamond; Zhiyong Qiu; Mihail Obrocea; Adrian Bot
Journal:  J Immunother       Date:  2011-09       Impact factor: 4.456

5.  A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.

Authors:  Gang Chen; Richa Gupta; Silvia Petrik; Marina Laiko; James M Leatherman; Justin M Asquith; Maithili M Daphtary; Elizabeth Garrett-Mayer; Nancy E Davidson; Kellie Hirt; Maureen Berg; Jennifer N Uram; Tianna Dauses; John Fetting; Elizabeth M Duus; Saadet Atay-Rosenthal; Xiaobu Ye; Antonio C Wolff; Vered Stearns; Elizabeth M Jaffee; Leisha A Emens
Journal:  Cancer Immunol Res       Date:  2014-08-12       Impact factor: 11.151

6.  CD8+ T cell immunity to 2009 pandemic and seasonal H1N1 influenza viruses.

Authors:  Kristin Scheible; Gang Zhang; Jane Baer; Mitra Azadniv; Kris Lambert; Gloria Pryhuber; John J Treanor; David J Topham
Journal:  Vaccine       Date:  2011-01-04       Impact factor: 3.641

7.  Programmed cell death-1 (PD-1) at the heart of heterologous prime-boost vaccines and regulation of CD8+ T cell immunity.

Authors:  Adrian Bot; Zhiyong Qiu; Raymond Wong; Mihail Obrocea; Kent A Smith
Journal:  J Transl Med       Date:  2010-12-14       Impact factor: 5.531

Review 8.  CTLA-4 blockade increases antigen-specific CD8(+) T cells in prevaccinated patients with melanoma: three cases.

Authors:  Jianda Yuan; Brian Ginsberg; David Page; Yanyun Li; Teresa Rasalan; Humilidad F Gallardo; Yinyan Xu; Sylvia Adams; Nina Bhardwaj; Klaus Busam; Lloyd J Old; James P Allison; Achim Jungbluth; Jedd D Wolchok
Journal:  Cancer Immunol Immunother       Date:  2011-04-05       Impact factor: 6.968

9.  Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.

Authors:  Suzanne George; Diana Miao; George D Demetri; Dennis Adeegbe; Scott J Rodig; Sachet Shukla; Mikel Lipschitz; Ali Amin-Mansour; Chandrajit P Raut; Scott L Carter; Peter Hammerman; Gordon J Freeman; Catherine J Wu; Patrick A Ott; Kwok-Kin Wong; Eliezer M Van Allen
Journal:  Immunity       Date:  2017-02-21       Impact factor: 31.745

10.  The Antitumor Efficacy of IL2/IL21-Cultured Polyfunctional Neu-Specific T Cells Is TNFα/IL17 Dependent.

Authors:  Vy Phan-Lai; Yushe Dang; Ekram Gad; Jennifer Childs; Mary L Disis
Journal:  Clin Cancer Res       Date:  2015-12-09       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.